Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name MCLA-145
Trade Name
Synonyms MCLA145|MCLA 145|anti-PD-L1/4-1BB bispecific antibody
Drug Descriptions

MCLA-145 is a bispecific antibody that binds to CD137 (4-1BB) and PD-L1 and simultaneously activates CD137 and inhibits PD-L1 signaling, which potentially relieves immune suppression resulting in reduced tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 539).

DrugClasses Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 TNFRSF9 Antibody 32
CAS Registry Number NA
NCIT ID C160772

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
MCLA-145 MCLA-145 0 1
MCLA-145 + Pembrolizumab MCLA-145 Pembrolizumab 0 0


Additional content available in CKB BOOST